Novartis

Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan
Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan
Biopharma Dive
Novartis
earnings
M&A
Endocyte
Flag link:
Are all new sales created equal?
Are all new sales created equal?
EP Vantage
GSK
Pfizer
Novartis
Flag link:
Amgen, Novartis and Banner Alzheimer's Institute Team on 2 Alzheimer's Prevention Trials
Amgen, Novartis and Banner Alzheimer's Institute Team on 2 Alzheimer's Prevention Trials
BioSpace
Amgen
Novartis
Alzheimer's disease
preventative medicine
Flag link:
7 drugmakers to watch during Q3 earnings
7 drugmakers to watch during Q3 earnings
Biopharma Dive
earnings
Novartis
Gilead Sciences
Amgen
Pfizer
GSK
AbbVie
Regeneron
Flag link:
Here's Why Momenta Pharmaceuticals Tumbled 13.5% on Friday
Here's Why Momenta Pharmaceuticals Tumbled 13.5% on Friday
Motley Fool
Momenta Pharmaceuticals
Teva Pharmaceuticals
Copaxone
Novartis
biosimilars
Glatopa
Flag link:
Sandoz free to launch Humira biosimilar in Europe following AbbVie deal
Sandoz free to launch Humira biosimilar in Europe following AbbVie deal
Pharmaforum
Novartis
Sandoz
AbbVie
Humira
biosimilars
Europe
Flag link:
Gilenya beats Copaxone head-to-head at higher dose, study finds
Gilenya beats Copaxone head-to-head at higher dose, study finds
Biopharma Dive
Novartis
Teva Pharmaceutical
MS
Copaxone
Gilenya
Flag link:
Roche and Novartis Strengthen Their Presence in the MS Market
Roche and Novartis Strengthen Their Presence in the MS Market
BioSpace
Genentech
Roche
Ocrevus
Novartis
siponimod
FDA
MS
multiple sclerosis
Flag link:
Novartis drug cuts serious complications in sickle cell disease
Novartis drug cuts serious complications in sickle cell disease
CP WIre
Novartis
sickle cell disease
crizanlizumab
Flag link:
Novartis cozies up to Silicon Valley with new lab
Novartis cozies up to Silicon Valley with new lab
Fierce Biotech
Novartis
innovation
San Francisco
Silicon Valley
R&D
Novartis Biome
Flag link:
Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in ’19
Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in ’19
Endpoints
Novartis
siponimod
MS
multiple sclerosis
Europe
Flag link:
Moody's picks 5 early winners in biosimilar market
Moody's picks 5 early winners in biosimilar market
Biopharma Dive
biosimilars
Pfizer
Biogen
Novartis
Amgen
Mylan Labs
Flag link:
Insight: How Novartis built a ‘money-filled moat’ to market Kymriah
Insight: How Novartis built a ‘money-filled moat’ to market Kymriah
Biopharma Reporter
Novartis
Kymriah
competition
drug marketing
CAR-T
Flag link:
Boston Pharma Doubles Pipeline with 2 Deals with Novartis and GSK
Boston Pharma Doubles Pipeline with 2 Deals with Novartis and GSK
BioSpace
Boston Pharmaceuticals
GSK
Novartis
Flag link:
Roche, Novartis grab FDA OK for new version of aging blockbuster Xolair
Roche, Novartis grab FDA OK for new version of aging blockbuster Xolair
Fierce Pharma
Roche
Novartis
Xolair
Xolair pen
FDA
Flag link:
Vas Narasimhan, Novartis CEO, explains reasons behind 2,100 jobs cut
Vas Narasimhan, Novartis CEO, explains reasons behind 2,100 jobs cut
GoinPharma
Novartis
layoffs
Vas Narasimhan
Pharma CEOs
Flag link:
Three new drugs will compete fiercely to revolutionize migraine treatment — with identical $6,900 price tags
Three new drugs will compete fiercely to revolutionize migraine treatment — with identical $6,900 price tags
Marketwatch
migraines
Eli Lilly
Emgality
Teva Pharmaceutical
Ajovy
Amgen
Novartis
Aimovig
Flag link:
Novartis signs manufacturing deal for Kymriah in China
Novartis signs manufacturing deal for Kymriah in China
BioCentury
Novartis
Kymriah
China
drug manufacturing
Flag link:
Mylan and Novartis to FDA: Where are the Suffixes?
Mylan and Novartis to FDA: Where are the Suffixes?
RAPS.org
Mylan Labs
Novartis
drug names
biosimilars
biologics
Flag link:
Novartis to cut 2,200 jobs in Switzerland to boost profits
Novartis to cut 2,200 jobs in Switzerland to boost profits
Pharmaforum
Novartis
layoffs
Switzerland
Flag link:

Pages